Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms
European Journal of Haematology · 2025-02 · 114 (2) · 315-324
DOI: 10.1111/ejh.14340 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 05.11.2024. Verfasst von Tobias Matthieu Benoit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, University Hospital Zurich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Lymphocyte Transfusion, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Allogeneic hematopoietic stem cell transplantation (HSCT) effectively treats high‐risk myeloid neoplasms, but relapses post‐HSCT, particularly in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), pose significant challenges. Donor lymphocyte infusion (DLI) has been utilized, but its effectiveness, especially in haploidentical settings, remains insufficiently clarified, and graft‐versus‐host disease (GvHD) poses a substantial risk.
Methods
In this retrospective cohort study, 57 patients with AML or MDS who received DLI after allogeneic HSCT at our center from 2002 to 2023 were analyzed. Herein, only preemptively or therapeutically applied DLI were included, and endpoints included overall survival (OS), progression‐free survival (PFS), and GvHD incidence post‐DLI.
Results
Median OS after DLI was 517 days, with a 1‐year OS of 62.5%. Factors associated with longer OS included patient age, HLA‐identical donor, post‐HSCT treatment naivety, and preemptive DLI indication. Haploidentical DLI was associated with inferior OS compared to HLA‐identical DLI; however, PFS and GvHD incidence post‐DLI did not differ significantly.
Conclusions
Our study findings indicate that OS rate is inferior in patients with relapsed AML or MDS treated with haploidentical DLI in comparison to those who received HLA‐identical DLI. Given the limitations of haploidentical DLI, alternative strategies, such as higher cell doses or combination treatment approaches, warrant further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, University Hospital Zurich, Zürich, Switzerland.
- Comprehensive Cancer Center Zurich, Zürich, Switzerland.
- Department of Medicine II, University Hospital Tübingen and University of Tübingen, Tübingen, Germany.
ORCID-Profile: Tobias Matthieu Benoit
Zitieren
APA
Benoit, T. M., Bachofner, A., Wolfensberger, N., Zaugg-Berger, Y., Manz, M. G., & Schneidawind, D. (2025). Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms. European Journal of Haematology, 114(2), 315-324. https://doi.org/10.1111/ejh.14340
Vancouver
Benoit TM, Bachofner A, Wolfensberger N, Zaugg-Berger Y, Manz MG, Schneidawind D. Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms. European Journal of Haematology. 2025;114(2):315-324. doi:10.1111/ejh.14340
BibTeX
@article{Benoit2025,
author = {Benoit, Tobias Matthieu and Bachofner, Adrian and Wolfensberger, Nathan and Zaugg-Berger, Yvonne and Manz, Markus Gabriel and Schneidawind, Dominik},
title = {Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms},
journal = {European Journal of Haematology},
year = {2025},
volume = {114},
number = {2},
pages = {315--324},
doi = {10.1111/ejh.14340}
}
EUVIMED